Maximilian Stahl
AML immunotherapy
Maximilian Stahl, MD
Boston, MA
United States
Dana-Farber Cancer Institute
Dr. Stahl is a member of the Adult Leukemia Group at Dana-Farber Cancer Institute and an Instructor of Medicine at Harvard Medical School. His research focus is on early phase clinical trials in myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes. He authored and co-authored more than 70 peer reviewed publications and has presented his research in multiple national and international meetings. He received the ASCO Conquer Cancer Foundation Young Investigator Award, the ASH HONORS Award and several abstract achievement awards. He is a member of the Editorial Board of Leukemia & Lymphoma and serves as a reviewer for several journals including Blood, Blood Advances and Clinical Cancer Research. He graduated from Hannover Medical School in Germany and completed his internal medicine residency and chief residency at Yale School of Medicine and his Hematology and Oncology fellowship at Memorial Sloan Kettering Cancer Center.
Program Name(s)
Translational Research Program
Project Title
Memory-like natural killer cells and venetoclax to eradicate measurable residual disease in AML
Lucas Ferrari De Andrade, PhD
New York, NY
United States
Icahn School of Medicine at Mount Sinai
Hello, I am Lucas Ferrari de Andrade and the principal investigator. I am from Brazil and with my wife we immigrated to the United States in 2014. We now have our two-year old son, born here in New York City. I worked for five years as postdoc at Harvard Medical School, where I developed a molecule that elicits potent anti-tumor immunity. Two years ago I started my own laboratory, to apply this molecule to acute myeloid leukemia (AML). My lab is very productive, in record timing we published our first research article. Our work is supporting a clinical trial by a pharmaceutical company, which does not financially support our lab and that will conduct the trial against solid tumors. Our research will show that AML can also be targeted. However, our research is having huge financial cost and we urgently need new awards to continue developing this potential treatment for AML. My scientific career has focused on the development of new molecules that can be used by doctors to treat cancer.
Program Name(s)
Translational Research Program
Project Title
Optimizing MICA/B antibody for AML by selective binding to Fc activating receptors
Simona Colla
Myeloma biology
Simona Colla, PhD
Houston, TX
United States
The University of Texas MD Anderson Cancer Center
Dr. Simona Colla is an associate professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center. Her laboratory works on understanding the mechanisms underpinning the pathogenesis and progression of multiple myeloma (MM) and myelodysplastic syndromes.
Program Name(s)
Career Development Program
Project Title
Validation of Critical 1q21 Vulnerabilities in multiple myeloma
Ryvu Therapeutics
AML, MDS
Ryvu Therapeutics, SA
Krakow,
Poland
TAP Partner
Ryvu Therapeutics is a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology using a proprietary discovery engine platform.
Program Name(s)
Therapy Acceleration Program
Project Title
A phase 1b study of RVU120, a novel CDK8 inhibitor, in patients with AML or high-risk MDS
Frederike Kramer
MPNs
Frederike Kramer, PhD
Boston, MA
United States
Brigham and Women’s Hospital
My current research explores the mechanisms by which epigenetic mutations drive the progression of myeloproliferative neoplasms (MPN). Throughout my graduate and now postgraduate development, my research focused on the biology and pathogenesis of MPN. After completing my BSc and MSc in Biotechnology, I pursued my doctoral training at Charité in Berlin, Germany, and completed my PhD at Freie Universität Berlin with summa cum laude. My graduate work focused on platelet-derived growth factor receptor signaling in myelofibrosis, the most aggressive type of MPN. Building on my prior experience in blood cancer research, I joined Prof. Ann Mullally’s laboratory at Brigham and Women’s Hospital for my postdoctoral training. Here, I am investigating the role of ASXL1 mutations during progression of MPN using mouse and human model systems.
Program Name(s)
Career Development Program
Project Title
Investigating the Role of ASXL1 Mutations in CALR-mutated Myeloproliferative Neoplasms
Jaehyuk Choi
T-cell lymphoma
Jaehyuk Choi, MD, PhD
Chicago, IL
United States
Northwestern University
Dr. Jaehyuk Choi is an Associate Professor of Dermatology and of Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine. He received his A.B. in Biochemical Sciences from Harvard, and his M.D. and Ph.D. degrees from Yale. He was a dermatology resident and a post-doctoral fellow in genetics at Yale. Since graduating from medical school, Dr. Choi is the recipient of the NIH New Innovator Award, the Damon Runyon Clinical Investigator Award, the Doris Duke Clinician Scientist Development Award, and is a recent inductee into the American Society for Clinical Investigation. Dr. Choi is a clinically active physician-scientist with a clinical and scientific focus on T cell lymphomas. His research group is interested in bench-to-bedside approaches to improve clinical care for patients with these diseases. To do so, he investigates the genetic mechanisms that underlie disease pathogenesis. This approach provides important clues as to what makes each patient unique and how to improve treatments for patients.
Program Name(s)
Career Development Program
Project Title
Identification of novel therapeutic strategies for aggressive subtypes of CTCL
Marina Konopleva
MDS/AML metabolism
Marina Konopleva, MD, PhD
Bronx, NY
United States
Albert Einstein College of Medicine
Dr. Konopleva is a Director of the Acute Leukemia Program and a Co-Director of the Translational Blood Cancer Institute at Einstein/Montefiore Cancer Center, NY. The PI is a physician-scientist with an active clinical practice where she treats MDS/AML patients on a routine basis outpatient and inpatient. She directs laboratory studying at understanding the pathogenesis and chemoresistance of AML and MDS stem/progenitor cells, with focus on metabolic and apoptosis regulators. Dr. Konopleva has joined Montefiore-Einstein in summer 2022 after long successful career as a physician-scientist at M.D. Anderson Cancer Center in Houston, Texas. She has brought multiple targeted agents from pre-clinical investigations into clinical trials, most notable BCL-2 inhibitor Venetoclax which in combination with low-intensity therapies has become a standard of care for older AML patients unfit for intensive chemotherapy and is being studied in high-risk MDS.
Program Name(s)
Discovery
Project Title
Targeting metabolic reprogramming in MDS and AML stem/progenitor cells
Daniel Thomas
Myelofibrosis
Daniel Thomas, MD PhD
Adelaide,
Australia
The University of Adelaide
Associate Professor Daniel Thomas is a Stanford-trained physician scientist who leads the Myeloid Metabolism Laboratory in the Precision Medicine Theme of the South Australian Health and Medical Research Institute at the University of Adelaide, Australia. As a clinician, Dan is passionate about direct bench to bedside translation and leads several innovative mutation-directed precision medicine clinical trials for blood cancers in Australia. Dan has published more than 48 peer-reviewed papers and he has received 16 prizes for his research including the Albert-Baikie Medal and highly competitive funding (CSL Centenary Fellowship, Snowdome and K99-R00 NCI Pathway to Independence award.
Program Name(s)
Translational Research Program
Project Title
Identification and Molecular Analysis of Pre-Myelofibrotic Stem Cells
Jalpa Doshi
Equity in Access
Jalpa Doshi, PhD
Philadelphia, PA
United States
Perelman School of Medicine at the University of Pennsylvania
Jalpa Doshi, PhD, is a Professor at the University of Pennsylvania and Director of Value Based Insurance Design Initiatives at the Center for Health Incentives and Behavioral Economics. Her research program aims to advance our understanding of how pharmaceuticals can be better accessed and utilized in the health care system to improve health outcomes while balancing costs. She has been a national leader in applying powerful health economics, outcomes research, and policy methods to address issues related to pharmaceutical access, costs, outcomes, and value. Her research has received widespread attention from the media including the New York Times and the Wall Street Journal and has directly influenced policies of public and private insurers. For example, she was the first to produce rigorous empirical research advocating for the closure of the “donut hole” (executed under the Affordable Care Act) and institution of an annual out-of-pocket maximum with “smoothing” (executed under the Inflation Reduction Act) under Medicare Part D. Her work documenting negative consequences of cost sharing among veterans was cited in arguments that kept the VA from increasing drug copayments. Her research on the burden of prior authorization policies for novel cholesterol-lowering agents was used to work with national insurers to appropriately reduce their policy restrictions. In recognition of her work, she has received numerous awards and honors from national and international organizations.
Program Name(s)
Equity in Access
Project Title
Sahand Hormoz
MPN
Sahand Hormoz, PhD
Boston, MA
United States
Dana-Farber Cancer Institute
Dr. Hormoz is an Assistant Professor with the Department of Systems Biology at Harvard Medical School and Department of Data Science at the Dana-Farber Cancer Institute. He obtained his PhD in Applied Physics from Harvard University. His postdoctoral studies were conducted jointly as a theorist at the Kavli Institute of Theoretical Physics (UCSB), and as an experimentalist at Caltech. Hormoz lab’s mission is to control biological systems to understand life and cure disease such as cancer. His lab develops new technologies for recording and measuring the molecular states of individual cells and computational frameworks for interpreting the large data sets that these measurements generate. Dr. Hormoz’s research on blood cancers has focused on reconstructing the history of cancer in individual patients to understand when cancer first occurs and how cancer cells expand in each patient.
Program Name(s)
Discovery
Project Title
Ann-Kathrin Eisfeld
Racial diversity in AML
Ann-Kathrin Eisfeld, MD
Columbus, OH
United States
The Ohio State University
Ann-Kathrin Eisfeld is a Tenure-track Assistant Professor and physician-scientist whose research focuses on acute myeloid leukemia genetics, as well as age-, gender- and race-associated differences in mutational landscape and prognostic significance of molecular markers. Her studies aim to identify prognostic factors and lead to refinements of disease classification and molecular subtypes, to enable personalized risk-stratification and treatment options. Dr. Eisfeld serves as director of the Clara D. Bloomfield Center for Leukemia Outcomes Research at The Ohio State University, which leads large-scale AML correlative studies directed at discovering associations between patient outcomes, genetic/genomic features, and clinical/demographic characteristics. The Center is dedicated to the long-term friend and mentor of countless Leukemia researchers and clinicians, Clara Bloomfield, and was established in 2020 to carry on her legacy of molecular prognostic association studies in AML and other hematologic malignancies.
Program Name(s)
Translational Research Program
Project Title
Improving the outcomes of young Black adults diagnosed with acute myeloid leukemia
Anouchka Laurent
T-cell lymphoma
Anouchka Laurent, PhD
New York, NY
United States
Columbia University Irving Medical Center
My research interests are the identification of genetic alterations responsible for leukemia and lymphoma development and the elucidation of the mechanisms leading to transformation in lymphoid diseases. My academic training and research experience give me an excellent background in multiple biological disciplines including cellular and molecular biology and genetics. I completed my PhD at the INSERM in France where I demonstrated the cooperation between an activating mutation of Jak3 and trisomy 21 in the development of cutaneous T cell lymphoma. I also identified a major cooperative role for the RAS/MAPK signaling pathway in the development of Down syndrome-associated B-cell acute lymphoblastic leukemia. Currently, I am a postdoctoral researcher at Columbia University, under the mentorship of Dr. Teresa Palomero, and I study the mechanisms of transformation in Peripheral T-cell lymphoma using multidisciplinary approaches from animal models to transcriptomic and epigenomic analysis.
Program Name(s)
Career Development Program